Menu
Curie Logo
Donate
  • Home

Clinical trials - page 5

Essais cliniques
Search for a clinical trial
Filter

195 result(s)

  • Saint-Cloud
    MIRASOL
    MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression.

    DIANA BELLO ROUFAI

  • Saint-Cloud
    MK 2140-010
    A Randomized, Open-label, Multisite, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP versus R-CHOP in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL) (waveLINE-010).

    CLEMENTINE SARKOZY

  • Breast cancer
    Paris
    MK-2870-010
    An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent;and in Combination with Pembrolizumab Versus Treatment of PhysicianÀs Choice in;Participants with HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer

    DELPHINE LOIRAT

  • Saint-Cloud
    MK-4280A-008
    Phase 3 Randomized Clinical Study of MK-4280A (coformulated;favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus PhysicianÀs Choice;Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma;(KEYFORM-008).

    Adrien GILBERT

  • Saint-Cloud
    MK3475 B96 ENGOT ov65
    A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (KEYNOTE-B96/ENGOT-ov65)

    DIANA BELLO ROUFAI

  • Saint-Cloud
    MK3475-826 (Keynote-826)
    A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (KEYNOTE-826)

  • Hématologie / cancers du sang
    Saint-Cloud
    MO44869_GLOASIS
    https://clinicaltrials.gov/study/NCT06558604?term=gloasis&rank=1

    CLEMENTINE SARKOZY

  • Paris
    MOST Plus
    My Own Specific Treatment : A two-period, multicenter, randomized, open-label, phase II study evaluating the clinical benefit of a maintenance treatment targeting tumor molecular alterations in patients with progressive locally-advanced or metastatic solid tumors

    ZAHRA CASTEL AJGAL

  • Saint-Cloud
    MS200647-0020/BREAST020
    A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With HMGA2-expressing Triple Negative Breast Cancer

    FRANCOIS-CLEMENT BIDARD

  • Childhood and adolescent cancers
    Paris
    MUCILA
    Multicenter double blind randomized placebo-controlled trial assessing the efficacy of low-level laser therapy in the prevention of chemotherapy-induced mucositis in children and young adults treated for a tumoral disease.

    CAMILLE CORDERO

  • Lymphoma
    Saint-Cloud
    MorningLyte
    This study is a phase III, randomized, open-label, international, multicenter, interventional trial, designed to compare the efficacy and safety of mosunetuzumab in combination with lenalidomide versus anti-CD20 monoclonal antibody (mAb) plus chemotherapy in patients with previously untreated FLIPI 2-5 follicular lymphoma.

    CLEMENTINE SARKOZY

  • Saint-Cloud
    NANORAD2
    Radiotherapy of Multiple Brain Metastases Using AGuIX® Gadolinium-chelated Polysiloxane Based Nanoparticles: a Prospective Randomized Phase II Clinical Trial.

  • Breast cancer
    Saint-Cloud
    NEOVAB
    Prospective Multicenter Pilot Study to Evaluate the Accuracy of Percutaneous Biopsy by Vacuum-assisted Biopsy (VAB) to Assess Pathological Complete Response in Patients With Clinical and Radiological Complete Response After Neoadjuvant Chemotherapy (NeoVAB)

  • ENT/Head and Neck Cancers
    Paris
    Nanoray-312
    A Phase 3 Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy Alone or Radiotherapy in Combination With Cetuximab for Platinum-based Chemotherapy-Ineligible Elderly Patients With LA-HNSCC

    MARIA LESNIK

  • Paris
    OCEAN-OT
    the Impact of Occupational Therapy : a Multicenter Randomized Controlled Trial (OCEAN-OT).

    FLORENCE ROLLOT TRAD

  • Saint-Cloud
    PACHA 01
    Postoperative Hepatic Arterial Chemotherapy in High-risk Patients as Adjuvant Treatment After Resection of Colorectal Liver Metastases - A Randomized Phase II/III Trial

  • Cancers urogénitaux
    Paris, Saint-Cloud
    PEACE 7
    A randomised Phase III trial with a factorial design evaluating the efficacy and safety of darolutamide and stereotactic dose escalated radiotherapy in patients with localised prostate cancer and high-risk features of relapse, from the Prostate Cancer Consortium in Europe (PEACE).

    GILLES CREHANGE, PIERRE GRAFF CAILLEAUD

  • Saint-Cloud
    PERSPECTIVE (MS202202-0002)
    A Phase II Single-Arm Study to Investigate Tepotinib Combined With Cetuximab in RAS/BRAF Wild-Type Left-Sided mCRC Patients Having Acquired Resistance to Anti-EGFR Antibody Targeting Therapy Due to MET Amplification (PERSPECTIVE)

  • Breast cancer
    Paris
    PRETORIA
    PROSPECTIVE EVALUATION OF A PREDICTIVE TOXICITY TEST POST RADIOTHERAPY AFTER MASTECTOMY WITH IMMEDIATE IMPLANT RECONSTRUCTION.

    YOULIA KIROVA

  • Childhood and adolescent cancers
    Paris
    PROVIN
    Study of a Propranolol (HEMANGIOL®) and Oral Metronomic Vinorelbine (NAVELBINE®) Combination for Children and Teenagers With Refractory/Relapsing Solid Tumors (PROVIN)

    ISABELLE AERTS GAJDOS

  • Sarcomas
    Saint-Cloud
    PRT2527-02
    A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib in Participants With R/R Hematologic Malignancies.

    CLEMENTINE SARKOZY

  • Saint-Cloud
    QPL-MDS
    Evaluation of a Question Prompt List for Patients With Myelodysplastic Syndromes (QPL-MDS)

    SANDRA MALAK

  • Myélome
    Saint-Cloud
    R5458-ONC-2245
    An Open-label, Randomized, Phase 3 Study of Linvoseltamab (REGN5458; anti-;BCMA x anti-CD3 Bispecific Antibody) Versus the Combination of Elotuzumab,;Pomalidomide, and Dexamethasone (EPd), in Patients with Relapsed/Refractory;Multiple Myeloma (LINKER-MM3).

    Cyrine ELLOUZ

  • Thymic tumors
    Paris
    RADIO-RYTHMIC-01 (IC 2020-09)
    Randomized, Multicenter, Phase III Trial to Assess Conformal Post-operative Radiotherapy vs. Surveillance After Complete Resection of Stage II/III Thymoma

    NICOLAS GIRARD

  • Cancers gynécologiques
    Paris
    RAINBO
    Refining Adjuvant treatment IN endometrial cancer Based On molecular features, TransPORTEC platform trials · p53abn - RED.

    AUDREY BELLESOEUR

  • Saint-Cloud
    REGOMUNE
    A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors

    SEGOLENE HESCOT

  • Childhood and adolescent cancers
    Paris
    RETINO-2018 (IC 2019-05)
    Ocular Conservative Treatment for Retinoblastoma: Efficacy of the New Management Strategies and Visual Outcome - RETINO 2018

    LIVIA LUMBROSO-LE ROUIC

  • Cancers gynécologiques
    Paris
    ROCSAN
    A multicentric randomized phase II/III evaluating TSR-042 (anti-PD-1 mAb) in combination with Niraparib (parpi) versus Niraparib alone compared to chemotherapy in the treatment of metastatic or recurrent endometrial or ovarian carcinosarcoma after at least one line of chemotherapy

    AUDREY BELLESOEUR

  • Saint-Cloud
    RTEP7 (IFCT-1402)
    Randomized Phase II-III Study of Personalized Radiotherapy Dose Redistribution in Patients With Inoperable Stage III Non-small Cell Lung Cancer and a Persistent FDG Uptake at 42 Grays During Concomitant Radio-chemotherapy.

    MARIE ANGE MASSIANI

  • Saint-Cloud
    SAFIR ABC10
    Clinical trial of precision medicine in patients with advanced biliary tract cancers (cholangiocarcinoma or gallbladder cancer).

<
1 ...57
>